Panobinostat - Cyclolab
Alternative Names: SBECD-enabled PanobinostatLatest Information Update: 09 Aug 2024
At a glance
- Originator Cyclolab
- Class Antineoplastics; Hydroxamic acids; Indoles; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Diffuse intrinsic pontine glioma; Lysosomal storage diseases; Multiple myeloma
Most Recent Events
- 24 Jul 2024 Panobinostat - Cyclolab is available for licensing as of 24 Jul 2024. https://cyclolab.hu/pipeline/ (Cyclolab pipeline, July 2024)
- 24 Jul 2024 Preclinical trials in Diffuse intrinsic pontine glioma in Hungary (unspecified route) prior to July 2024 (Cyclolab pipeline, July 2024)
- 24 Jul 2024 Preclinical trials in Lysosomal storage diseases in Hungary (unspecified route) prior to July 2024 (Cyclolab pipeline, July 2024)